Literature DB >> 10208223

The treadmill test--where to stop and what does it mean?

G Ramamurthy1, J E Kerr, D Harsha, M E Tavel.   

Abstract

The prognostic utility of an exercise ECG test depends upon having an adequate workload to stress the cardiac system. A negative stress test, in which there are no adverse clinical or ECG findings, and in which an adequate workload is achieved, stratifies patients into a low-risk group. The 1997 American Heart Association guidelines imply that any index of workload--heart rate, rate-pressure product, or exercise duration in multiples of resting O2 consumption (METS)--could be used to indicate that adequate stress was achieved. However, while there is considerable evidence supporting the use of METS as a strong independent prognostic variable, there is less support for the use of rate-pressure product or heart rate. Indeed, there is evidence that a high heart rate at a low workload carries an adverse prognosis. Further research is needed to identify the number of METS achieved that would define an adequate workload. In the meantime, a review of the literature suggests that 7 to 10 METS is a reasonable ballpark figure of the minimum workload in patients with a negative stress test that would imply a favorable outcome.

Entities:  

Mesh:

Year:  1999        PMID: 10208223     DOI: 10.1378/chest.115.4.1166

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

Review 1.  Assessing patients with possible heart disease using scores.

Authors:  K Shetler; A Karlsdottir; V Froelicher
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

2.  An examination of psychosocial correlates of exercise tolerance in cardiac rehabilitation participants.

Authors:  Shawn N Fraser; Wendy M Rodgers
Journal:  J Behav Med       Date:  2009-12-06

3.  Improving the positive predictive value of exercise testing in women.

Authors:  Y K Wong; S Dawkins; R Grimes; F Smith; K D Dawkins; I A Simpson
Journal:  Heart       Date:  2003-12       Impact factor: 5.994

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.